Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power

Slides:

Advertisements

Similar presentations

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Advertisements

An Academic Research Organization of Brigham and Women’s Hospital and Harvard Medical School LAPLACE-TIMI 57 Primary Results A Double-blind, Randomized,

Clinical Trial Results. org METEOR Trial Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. John R.

Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:

Baseline characteristics and eligibility criteria of participating trials Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:

Kendrick Sparks, PGY3 September 17, 2015

R1. 이정미 / prof. 김우식. INTRODUCTION Reduction in low-density lipoprotein (LDL) cholesterol levels has proved to be highly effective in reducing rates of.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from participants in 26 randomised trials Lancet 2010;

Results of the GLAGOV Trial

Effect of the PCSK9 Inhibitor, Evolocumab, on the Composition of Coronary Atherosclerosis: Insights from the GLAGOV Trial SJ Nicholls, H Kassahun, DM Brennan,

NICE –CG 181 Continuum of CVD Risk and its treatment

Results of the GLAGOV Trial

Copyright © 2006 American Medical Association. All rights reserved.

European Society of Cardiology 2017 Clinical Trial Update I

Copyright © 2003 American Medical Association. All rights reserved.

LDL cholesterol in CKD—to treat or not to treat?

Statin Myopathy (AHA/ACC/NHLBI)

Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes Louise Bowman & Martin Landray on.

PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation.

Recommendation of NLA Expert Panel on Treatment With PCSK9 Inhibitors

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels† Eli.

Updates and Perspectives in Diabetic Dyslipidemia

Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA

LDL Established Target for Cardiovascular Risk

Current Dyslipidemia Management Guidelines Residual Risk.

CathPCI-NCDR Registry Mortality (STEMI)

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

PCSK9 Loss-of-function Mutations PCSK9-Mediated Degradation of LDL-R.

GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Figure 1 Newly discovered mechanistic pathways

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.

LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

Statin Class in Session

An Update on PCSK9 Inhibitors

Nat. Rev. Cardiol. doi: /nrcardio

Evaluating LDL-C Recommendations

What's New in Dyslipidemia?

62-year-old Man With Unstable Angina

Statin Class in Session

Figure 1 Overview of lipoprotein metabolism and effects of novel lipid-modulating approaches Figure 1 | Overview of lipoprotein metabolism and effects.

PCSK9 Inhibitors and Cardiovascular Outcomes

% decrease in LDL-C at 24 weeks from baseline

% decrease in LDL-C at 24 weeks from baseline

ODYSSEY FH I and II Trial design: Participants with heterozygous familial hypercholesterolemia on statin therapy were randomized to alirocumab 75 mg SQ.

PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?

Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia Joep C. Defesche, PhD,

New LDL-C Lipid Targets

Radical New Concepts in Lipid Management

Emerging Approaches To Improve LDL-C Reduction in Hypercholesterolemia

Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized.

Updates in Cardiovascular Medicine

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9

Monoclonal Antibodies in CVD: What Does the Future Hold?

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled.

Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.

PCSK9 Mutations PCSK9 Loss-of-function Mutations.

LDL Cholesterol.

Reducing Risk for CV Outcomes

LDL cholesterol in CKD—to treat or not to treat?

New Lipid-Lowering Therapies

An Update on PCSK9 Inhibitors

RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.

Omega-3s vs Pure EPA in Clinical Practice

Flow of study participants

LDL-c reductions below 1

PCSK9 Inhibitors and Real-World Evidence

Shared-Decision Making in Dyslipidemia

Medication intensity (ALLP) changes between baseline and 6 months, by (not) being low-density lipoprotein-cholesterol (LDL-C) target at baseline for nurse-coordinated.

Presentation transcript:

Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power

PRIMO: Observational Study in 7924 Patients

Genetics: PCSK9

PCSK9 Monoclonal Antibody vs Placebo on LDL-C Levels

Dosing and Administration

LAPLACE-TIMI 57: AMG 145 Q2W Dose Response -- Change in LDL-C From Baseline

Cholesterol Treatment Trialists Collaboration (N = 170,000)

Lipid-Lowering Goals: Back to Nature?

Impact of LDL-C on Plaque Progression

Global Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)

PCSK9: Barriers

Large Unmet Medical Need

Thank you for participating in this activity Thank you for participating in this activity. To proceed to the CME posttest, click the Earn CME Credit link on this page.